This is a news story, published by TechCrunch, that relates primarily to Dharmil Sheth news.
For more Dharmil Sheth news, you can click here:
more Dharmil Sheth newsFor more stocks trading & speculation news, you can click here:
more stocks trading & speculation newsFor more news from TechCrunch, you can click here:
more news from TechCrunchOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best business news, entertainment news, world news, and much more. If you like stocks trading & speculation news, you might also like this article about
Indian online pharmacy. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest Indian startup news, American global asset firm news, stocks trading & speculation news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
PharmEasyTechCrunch
•
77% Informative
PharmEasy , once valued at $5.6 billion , is still about 92% below its peak valuation.
In April the startup said it had launched a rights issue to raise about $417 million .
The rights issue, which allows existing investors to buy new shares in the firm at a much lower valuation, was oversubscribed, PharmEasy co-founder Dharmil Sheth said.
VR Score
77
Informative language
75
Neutral language
65
Article tone
informal
Language
English
Language complexity
43
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
short-lived
External references
1
Source diversity
1
Affiliate links
no affiliate links